Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Acella Pharmaceuticals, LLC
EIR
•Acella Pharmaceuticals, LLC•March 29, 2019

Acella Pharmaceuticals, LLC – FDA EIR, Mar 29, 2019

Record Details

Acella Pharmaceuticals, LLC underwent an FDA inspection from March 25-29, 2019, focusing on Postmarketing Adverse Drug Experience (PADE) reporting. This inspection was conducted under compliance program 7353.001 by the Center for Drug Evaluation and Research, Postmarketing Safety Branch. The company, an own-label distributor of pharmaceutical products and dietary supplements, was cited for two main objectionable conditions, both repeat observations from a previous inspection. The primary violations included the late submission of annual reports for Gabapentin Oral Solution (ANDA 076403), as required by 21 CFR 314.81(b)(2). Additionally, Acella Pharmaceuticals failed to submit annual Periodic Adverse Drug Experience Reports (PADERs) within 60 days of the anniversary date for both Gabapentin Oral Solution and Phenytoin Sodium Injection (ANDA 040573), a violation of 21 CFR 314.80(c)(2). Management indicated they were attempting to secure a waiver for reporting date changes and were unclear on PADER submission responsibilities in the absence of adverse events. Beyond the formal observations, the FDA investigator discussed concerns regarding deficiencies in existing Adverse Drug Experience procedures, outdated quality agreements with contract manufacturers, and incorrect reporting dates on aggregate reports. Acella Pharmaceuticals management acknowledged these issues and committed to providing a written response to the FDA within 15 business days. The firm also initiated voluntary corrections during the inspection, including revising draft procedures and correcting dates on certain PADERs.

Company
Acella Pharmaceuticals, LLC
Inspection date
March 29, 2019
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Sharon Leyva (company_representative)
  • Becky Clasper (recipient)
  • Harold Deas (recipient)
  • Allen E. Fields (company_representative)
  • Vanessa E. Coulter
View Company Profile

ID · cb1f9e55-2e6c-4e53-a434-cb3b36203f29

Violation Codes3
21 CFR 314.80(c)(2)21 CFR 820.19821 CFR 314.81(b)(2)

Full citation text and observation details available on the Dashboard.

Other documents for Acella Pharmaceuticals, LLC
  • 483 - 2024-12-18December 18, 2024
  • 483 - 2023-02-10February 10, 2023
  • 483 - 2021-09-17September 17, 2021
  • EIR - 2020-01-07January 7, 2020
  • WARNING_LETTER - 2020-01-07January 7, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Acella Pharmaceuticals, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.